Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs.
Since renal failure itself creates an immunocompromised situation, malignant tumours in haemodialysis patients are increasing due to the prolonged lifespan of these patients. In treating these patients with anticancer agents, dosage reduction is often recommended to avoid adverse drug reactions, particularly for drugs with extensive renal excretion. On the other hand, if an anticancer drug is removed significantly by haemodialysis, dosage increase would be required to ensure adequate therapeutic efficacy. We address in this review the clinical pharmacokinetic aspects of antineoplastic therapy, and the application of pharmacokinetic principles to the adjustment of dosage of anticancer agents in haemodialysis patients.
Tomita
Masatoshi
M
Division of Obstetrics and Gynecology, Niigata Prefectural Tokamachi Hospital, Niigata, Japan. mastom@lapis.plala.or.jp
Aoki
Yoichi
Y
Tanaka
Kenichi
K
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D005260:Female; D006207:Half-Life; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D008297:Male; D008657:Metabolic Clearance Rate; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D006435:Renal Dialysis
D000970:Antineoplastic Agents